[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastatic-testicular-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastatic-testicular-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100612821","the-tasty-steering-study-100612821",false,"NCT07258563","The TASTY-steering Study","Taste Steering in Patients With Cancer Who Are Treated With Chemotherapy: a Multicentre Randomized Intervention Trial","TASTY-steering","Inclusion Criteria:\n\n* Age ≥18 and ≤70 years\n* Indication to start chemotherapy for:\n\n  * Metastatic triple negative breast cancer\n  * Metastatic testicular cancer\n  * Stage II-IV diffuse large B cell lymphoma\n* Chemotherapy scheduled to start in the next 6 weeks\n* Consuming solid foods and drinks is possible\n* ≤50% of recommended daily intake in kcal consists of oral nutritional supplements\n* Oral mucositis grade ≤2 (Common Terminology Criteria for Adverse Events, version 5.0)\n* Ability to comply with all protocol-required actions\n* Written informed consent\n* For the intervention phase only: subjective change in taste since start of chemotherapy\n\nExclusion Criteria:\n\n* Pregnancy\n* Currently experiencing taste or smell problems\n* Previous or current radiotherapy of head and neck region\n* Enteral feeding through tube or parenteral feeding\n* Participation in another clinical trial aimed at preventing or treating taste and\u002For smell alterations\n* Chronic (\\>1 month) high dose corticosteroids (\\>10 mg prednisone\u002Fday or equivalent).","ALL","18 Years","70 Years",{"count":21,"type":22},201,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a multicentre non-blinded randomised intervention trial with a parallel cluster design. The multicentre study will be performed at 12 hospitals in the Netherlands. A parallel cluster design per hospital was selected to prevent contact between participants in the same hospital who are randomised into different study arms. Such contact may result in bias as it may allow for patients in the control arm to be informed about elements of taste steering.\n\nTo examine the effect of at-home taste steering versus standard care on food enjoyment, the obtained results and outcomes will be measured 1) at baseline before chemotherapy is started, 2) at week 0 when taste or smell alterations occur, and 3) after 6 weeks. The taste steering will take place at home. The control group will receive usual care. Questionnaires will be filled in online at home, while taste and smell tests and saliva collection will be conducted either at home or in the hospital during regular visits. Patients in both study arms are contacted by their dietitian every 3 weeks.\n\nSome hospitals have implemented elements of taste steering. However, these elements are focused on patients who are admitted to the hospital, and therefore only interfere to a limited extent with the present study that is directed at patients managing their taste alterations at home. Experience with the Smaakpupil tool indicates that the algorithm reaches saturation after 3-4 weeks. Therefore, an intervention period of 6 weeks has been selected.",[28,29,30],"Metastatic Triple Negative Breast Cancer","Metastatic Testicular Cancer","Stage II-IV Diffuse Large B Cell Lymphoma",[32],"Taste Alterations","RECRUITING","2026-07-13",{"date":36,"type":37},"2026-07-15","ACTUAL",{"date":39,"type":37},"2025-06-06",{"date":41,"type":22},"2028-07",{"name":43,"class":44},"University Medical Center Groningen","OTHER",11,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100484488","impact-of-a-physical-activity-program-to-reduce-long-term-cancer-related-fatigue-in-metastatic-testicular-germ-cell-tumor-patients-100484488","NCT05588700","Impact of a Physical Activity Program to Reduce Long-term Cancer-related Fatigue in Metastatic Testicular Germ Cell Tumor Patients","A National, Multicenter, Phase III Randomized Controlled Trial to Assess the Impact of a One-year Supervised Physical Activity Program to Reduce Long-term Cancer-related Fatigue in Metastatic Testicular Germ Cell Tumor Patients","STARTER","Inclusion Criteria:\n\n* Men ≥18 years\n* With a metastatic germ cell tumor histologically confirmed (seminoma and non-seminoma)\n* Who have already undergone an orchidectomy (since the 16th december, this criteria was deleted).\n* Having a first line of chemotherapy planned with BEP, EP or VIP\n* Having a smartphone (i.e. to connect the activity tracker)\n* PS \\\u003C or = 2\n* Whose ability to practice an adapted physical activity (APA) has been certified by a medical certificate issued by the referring oncologist or the investigating physician\n* Available and willing to participate in the study for the duration of the intervention and follow-up,\n* Able to understand, read and write French,\n* Affiliated with a social security scheme,\n* Having dated and signed an informed consent.\n\nExclusion Criteria:\n\n* Presence of symptomatic bone and\u002For brain metastases\n* Central nervous system involvement with neurological deficits preventing walking\n* History or coexistence of another primary cancer (apart from in situ cancer of any location and\u002For basal cell skin cancer and\u002For basal cell skin cancer and\u002For a cancer in complete remission for more than 3 years),\n* Contraindication to physical activity (e.g. uncontrolled hypertension, uncontrolled heart disease) uncontrolled heart disease),\n* Unable to be followed for medical, social, family, geographical or psychological reasons, during the entire study period,\n* Deprived of liberty by judicial or administrative decision, or adults protected by law,\n* Concurrent participation in another study in PA.","MALE",{"count":56,"type":22},236,[25],"Testicular germ cell tumor (TGCT) is the most common malignancy in men between 15 and 40 years. Although TCGT survivors have a good survival prognosis, they suffer from short- and long-term sequelae such as chronic fatigue, psychological disorders, cardiovascular toxicities and second malignancies. The benefits of physical activity (PA) during treatments have been demonstrated in cancer patients to improve quality of life (QoL) and physical fitness and to reduce fatigue. However, few PA programs have been proposed to TGCT patients and their effects on sequelae have not been assessed yet. A growing body of evidence links treatment-related alteration in the gut microbiota to sequelae of cancer survivors, including fatigue and cardiovascular toxicities. Also, PA has been known as a possible modulator of the gut microbiota composition. To date, no study has been conducted to examine how the gut microbiota and its metabolites moderate the effect of PA on fatigue and other late effects in TGCT survivors. The objectives will be to assess the impact of a PA program on fatigue and other sequelae and to investigate how the gut microbiota and its metabolites moderate the associations between PA and sequelae. We will conduct a prospective, multicenter, phase III, randomized controlled trial of a one-year supervised PA program. 236 men with metastatic TGCT and eligible for a first line of chemotherapy will be randomly assigned to either PA intervention or control arm. All patients will benefit from a connected activity tracker and PA recommendations. In the intervention arm, PA will be based on supervised sessions and motivational interviews. The primary endpoint (fatigue) will be assessed at 3 years. The trial will provide novel insights into the impact of PA on fatigue and other sequelae in TGCT survivors with understanding a potential underlying mechanism of gut microbiota. This evidence will support the development of targeted PA guidelines to improve QoL and reduce sequelae in TGCT survivors.",[29],[61,62,63],"fatigue","sequelae","gut microbiota composition","2026-03-26",{"date":66,"type":37},"2026-03-31",{"date":68,"type":37},"2025-01-14",{"date":70,"type":22},"2038-01-14",{"name":72,"class":44},"Centre Leon Berard",12]